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Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] 
reductase inhibitors) are widely prescribed for the treatment of 
hypercholesterolemia and have been shown to reduce cardiovascu-
lar events and mortality in several randomized clinical trials (1–3). 
Statins inhibit the conversion of HMG-CoA to the cholesterol 
precursor mevalonate, which is the rate-limiting step in cholesterol 
biosynthesis. Mevalonate is also the precursor compound for other 
isoprenoids, including farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate, which are critical for posttranslational modifica-
tion of proteins involved in cell growth, including both the RAS 
and RHO oncogenes (4,5). Consequently, statins are hypothesized 
to have antineoplastic benefits, possibly through inhibition of RAS 
signaling.
Several epidemiological studies have evaluated the association 
between statin use and the risk of colorectal cancer and yielded 
inconsistent results. A large retrospective case–control study in 
Israel demonstrated a 47% reduction in the risk of colorectal can-
cer after 5 years of statin use (6). Likewise, two large meta-analyses 
reported 12% and 13% reductions in colorectal cancer risk (7,8), 
respectively, after as little as 6 months of use. Nonetheless, several 
retrospective and prospective studies have offered conflicting 
results, and two other meta-analyses failed to confirm that statin 
use is associated with a reduction in the risk of cancer overall (9) or 
colorectal cancer specifically (10).
Beyond studies assessing the chemopreventative role of statins, 
the relationship between statin use and colon cancer patient 
outcome is unknown. Because of continued interest in the role of 
statin use in cancer risk and outcome, the National Surgical 
Adjuvant Breast and Bowel Project initiated the Statin Polyp 
Prevention Trial (protocol P-5), which is currently randomly 
assigning patients with resected stage I or II colon cancer to rosu-
vastatin (10 mg daily) or placebo treatment arms for a period of 5 
years. The primary endpoint of this study is adenomatous polyp 
formation, metachronous colorectal carcinoma, or colon cancer 
recurrence. Results from this trial are not anticipated for several 
years. Therefore, to address the gap in knowledge, we prospectively 
ARTICLE
Relationship Between Statin Use and Colon Cancer Recurrence 
and Survival: Results From CALGB 89803
Kimmie Ng, Shuji Ogino, Jeffrey A. Meyerhardt, Jennifer A. Chan, Andrew T. Chan, Donna Niedzwiecki, Donna Hollis, Leonard 
B. Saltz, Robert J. Mayer, Al B. Benson III, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Monica 
M. Bertagnolli, Alan P. Venook, Charles S. Fuchs
Manuscript received January 28, 2011; revised July 14, 2011; accepted July 19, 2011.
Correspondence to: Kimmie Ng, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 
(e-mail: kng4@partners.org).
 Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the 
impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown.
 Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized 
adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use 
and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated 
by Kaplan–Meier curves and log-rank tests in the overall study population and in a subset of patients stratified 
by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simulta-
neous impact of confounding variables. All statistical tests were two-sided.
 Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among 
statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence 
interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of 
cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival 
outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (Ptrend = .63, .63, 
and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation 
status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (Pinteraction = .84, .67, 
and .98 for DFS, RFS, and OS, respectively).
 Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in 
patients with stage III colon cancer, regardless of KRAS mutation status.
  J Natl Cancer Inst 2011;103:1540–1551
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Figure 1. Flow chart of patient selection 
from the Cancer and Leukemia Group B 
(CALGB) trial 89803 for inclusion in the 
study cohort. Q1 = Questionnaire 1, Q2 = 
Questionnaire 2.
Classifications included white, Hispanic, black, Asian, Native 
Hawaiian, Native American, Indian, Filipino, other, and unknown. 
These and other demographic information were reported by each 
CONTEXT AND CAVEATS
Prior knowledge
Although several studies have investigated the potential chemo-
preventative activity of statins, and conflicting findings on the rela-
tionship between statin use and the risk of colon cancer have been 
reported, the relationship between statin use and outcome among 
colon cancer patients has not been studied.
Study design
The relationship between statin use and disease-free, recurrence-
free, and overall survival among 842 colon cancer patients enrolled 
in a randomized clinical trial of adjuvant chemotherapy was ana-
lyzed. A subanalysis by KRAS mutation status was also done 
because studies have suggested that statin use may inhibit RAS 
signaling.
Contribution
No differences between disease-free, recurrence-free, or overall sur-
vival between statin users and nonusers were observed in the general 
study population or in a subanalysis by KRAS mutation status.
Implications
Statin use during and after adjuvant chemotherapy for the treatment 
of colon cancer may not improve survival outcomes. A randomized 
placebo-controlled prevention trial to investigate the effect of statin 
use on colon cancer risk and recurrence is currently underway.
Limitations
The study of statin use depended on patient self-reports in response 
to a questionnaire. Also, the impact of different statins on patient 
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examined the relationship between statin use and cancer recur-
rence or death from any cause, cancer recurrence only, and overall 
mortality in stage III colon cancer patients enrolled in a completed 
National Cancer Institute–sponsored clinical trial of adjuvant che-
motherapy. In addition, given the hypothesis that statin use may 
inhibit RAS signaling, we also investigated the association between 




Patients in this prospective cohort study were participants in the 
Cancer and Leukemia Group B (CALGB) trial for stage III colon 
cancer (89 803) that compared adjuvant bolus 5-fluorouracil and 
leucovorin with the combination of irinotecan, bolus 5-fluoro-
uracil, and leucovorin (11). Patients were enrolled from April 1999 
to May 2001. A self-administered questionnaire that captured diet 
and lifestyle habits was completed by patients midway through 
their therapy (4 months after surgery, Questionnaire 1) and again 
6 months after the completion of treatment (14 months after sur-
gery; Questionnaire 2). The protocol amendment to survey diet 
and lifestyle was activated after the first 87 patients were enrolled; 
therefore, 1177 patients were eligible for the companion study 
(Figure 1).
Patients were eligible for the treatment trial if they had under-
gone a complete surgical resection of their primary tumor within 
56 days of study entry and had regional lymph node metastases but 
no distant metastases. Patients were required to have a baseline 
Eastern Cooperative Oncology Group performance status of 0–2 
and adequate bone marrow, renal, and hepatic function. Median 
household income was estimated using concurrent census data 
determined by the patient zip code. Race/ethnicity was self-reported 
and recorded in the hospital database at each participating center. 
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participating center to the CALGB Statistical Center. All patients 
gave informed consent, and the study protocol was approved by 
the review board of each institution.
Statin Assessment
Statin use was assessed by Questionnaire 2 after the completion of 
adjuvant chemotherapy. Only patients who did not experience 
disease recurrence or death before the second questionnaire were 
included in the analyses. Participants were asked whether they take 
any of several medications, including statin cholesterol–lowering 
drugs (eg, lovastatin [Mevacor], pravastatin [Pravachol], simvas-
tatin [Zocor], and atorvastatin [Lipitor]). Those who reported 
current statin use were asked to provide the number of years of use 
(0–2, 3–5, or ≥6 years). We excluded patients whose cancer 
recurred or who died within 90 days of their statin assessment to 
avoid potential bias related to an underlying illness.
KRAS Mutation Assessment
Methods for determining the presence of a KRAS mutation have 
been previously described (12). Briefly, polymerase chain reactions 
and pyrosequencing spanning KRAS codons 12 and 13 were per-
formed and validated against Sanger sequencing method (13). 
Polymerase chain reaction amplification primers for KRAS pyrose-
quencing were: KRAS-F, forward, 5’-nnn ggc ctg ctg aaa atg act 
gaa-3’ and KRAS-R, reverse biotinylated primer, 5’-tta gct gta tcg 
tca agg cac tct-3’. Sequencing primers were 5’-tgt ggt agt tgg agc 
tg-3’ and 5’-tgt ggt agt tgg agc t-3’. Similar baseline characteris-
tics were observed for patients with available KRAS data and 
those without available tumor tissue. Moreover, similar tumor 
recurrence and mortality rates were observed among these two 
populations (13).
Study Endpoints
Study endpoints were calculated from the time of completion of 
statin assessment on Questionnaire 2 rather than from the start of 
trial treatment to avoid any biases from altered medication use 
and/or exposure during the period of active chemotherapy. The 
primary endpoint was disease-free survival (DFS), defined as the 
time from the completion of Questionnaire 2 to tumor recurrence, 
occurrence of a new primary colon cancer, or death from any 
cause. Recurrence-free survival (RFS) was defined as the time from 
the completion of Questionnaire 2 to tumor recurrence, death 
with evidence of recurrence, or occurrence of a new primary colon 
tumor; patients who died without known recurrence were cen-
sored at the last documented evaluation. Finally, overall survival 
(OS) was defined as the time from completion of Questionnaire 2 
to death from any cause.
Statistical Analyses
Results from the CALGB trial for stage III colon cancer com-
paring adjuvant bolus 5-fluorouracil and leucovorin with the com-
bination of bolus 5-fluorouracil, leucovorin, and irinotecan have 
been previously described (11), and results from the two chemo-
therapy treatment arms were similar; thus, data for patients were 
combined and analyzed according to categories of statin use after 
adjuvant chemotherapy for this study. Baseline characteristics were 
compared between statin users and nonusers using Fisher exact test 
for 2 × 2 categorical comparisons, a x2 test for other categorical 
comparisons, and the Kruskal–Wallis test for continuous variables. 
The median follow-up time was determined by calculating the 
median survival time of patients still alive on March 31, 2009.
Multivariable models were adjusted for age (in years, as a con-
tinuous variable), sex (male or female), family history of colorectal 
cancer (yes or no), and Eastern Cooperative Oncology Group 
performance status at the initiation of chemotherapy (0 or 1–2). 
A performance status of 0 indicated that a patient was fully active, 
a status of 1 indicated that the patient was restricted in physically 
strenuous activity but ambulatory and able to carry out light work, 
and a status of 2 indicated that the patient was ambulatory and 
capable of all self-care but unable to carry out any work activities 
but up and about for more than 50% of the waking hours. We 
adjusted for the depth of invasion through the bowel wall by 
assigning T1 or T2 when the level of invasion was through the 
bowel wall but not beyond the muscle layer, whereas T3 or T4 
was assigned when the level of invasion through the bowel wall 
was beyond the muscle layer. The number of positive lymph nodes 
(1–3 or ≥4), perineural invasion (yes or no), and extravascular 
invasion (yes or no) were other pathological variables that were 
included in the model. Finally, we also adjusted for the level of 
postoperative carcinoembryonic antigen present in serum before 
the initiation of chemotherapy (<5 or ≥5 ng/mL), the treatment 
arm (bolus 5-fluorouracil plus leucovorin or the combination of 
irinotecan, bolus 5-fluorouracil, and leucovorin), body mass index 
(BMI) at the initiation of chemotherapy (as a continuous variable), 
physical activity (metabolic equivalent task hours per week, as 
a continuous variable), Western pattern diet (as a continuous 
variable), and consistent aspirin use (any aspirin use on both 
Questionnaires 1 and 2). Continuous variables with missing values 
were imputed with the median value (n = 2 for BMI and for phys-
ical activity), and categorical covariables with missing values were 
coded with indicator variables. DFS, RFS, and OS were examined 
using Kaplan–Meier curves (14) and the log-rank test (15) in the 
overall population and in patients stratified by KRAS mutation 
status. Cox proportional hazards regression was used to determine 
the simultaneous impact of potential confounders (16). The pro-
portionality of hazards assumption for the effect of statin use was 
satisfied by examining it as a time-dependent covariable in the model 
(17). The time-dependent statin covariable was non-statistically 
significant, indicating that the assumption of proportional hazards 
was appropriate. We tested for linear trend by entering the median 
value of each category of duration of statin use as a continuous 
variable in the model (18). Statistical interactions between statin 
use and potentially modifying covariables were assessed using 
Wald test of cross-product terms. Adverse events were graded 
according to the National Cancer Institute Common Toxicity 
Criteria version 2.0, and logistic regression was performed to 
examine the association between statins and grade 3 and higher 
toxic effects.
All statistical tests were two-sided and P values less than .05 
were considered statistically significant. The sample size for the 
cohort was determined by the chemotherapy treatment trial, which 
had 82% power to detect a hazard ratio (HR) for death from any 
cause of 0.77 on the basis of an estimated 356 deaths among 1260 
patients. In a post hoc calculation of power on the basis of the 
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Table 1. Baseline characteristics by statin use reported after adjuvant chemotherapy in patients from the Cancer and Leukemia Group B 
trial 89803*
Characteristic
Statin use after completion of adjuvant chemotherapy
No (n = 708) Yes (n = 134) P†
Median age (range), y 59.0 (21–85) 64.0 (47–80) <.001
Sex, No. (%) 708 (100) 134 (100) .11
 Male 390 (55.1) 84 (62.7)
 Female 318 (44.9) 50 (37.3)
Race/ethnicity, No. (%) 705 (99.6) 134 (100) .42
 White 628 (89.1) 121 (90.3)
 Black 50 (7.1) 6 (4.5)
 Other 27 (3.8) 7 (5.2)
Median household income (range),  
  US dollars‡
40 742 (17 963–122 234) 40 708 (21 203–122 956) .69
Family history of colorectal cancer, No. (%) 708 (100) 134 (100) .63
 Yes 137 (19.4) 23 (17.2)
 No 571 (80.6) 111 (82.8)
Baseline ECOG performance status, No. (%) 692 (97.7) 133 (99.3) .91
 0 524 (75.8) 100 (75.2)
 1–2 168 (24.3) 33 (24.8)
Invasion through bowel wall  
  (T stage), No. (%)
691 (97.6) 133 (99.3) .08
 T1 and T2 97 (14.0) 27 (20.3)
 T3 and T4 594 (86.0) 106 (79.7)
Positive lymph nodes (N stage), No.  
  of patients (%)
693 (97.9) 133 (99.3) .48
 1–3 (N1) 465 (67.1) 94 (70.7)
 ≥4 (N2) 228 (32.9) 39 (29.3)
Grade of differentiation, No. (%) 693 (97.9) 133 (99.3) .17
 Well differentiated 45 (6.5) 5 (3.8)
 Moderately differentiated 488 (70.4) 104 (78.2)
 Poorly differentiated or undifferentiated 160 (23.1) 24 (18.0)
Lymphovascular invasion, No. of patients (%) 686 (96.9) 128 (95.5) .67
 Yes 190 (27.7) 38 (29.7)
 No 496 (72.3) 90 (70.3)
Perineural invasion, No. of patients (%) 676 (95.5) 126 (94) 1.00
 Yes 40 (5.9) 7 (5.6)
 No 636 (94.1) 119 (94.4)
Extravascular invasion, No. of patients (%) 677 (95.6) 125 (93.3) .73
 Yes 58 (8.6) 9 (7.2)
 No 619 (91.4) 116 (92.8)
KRAS mutation, No. of patients (%) 326 (46.0) 68 (50.7) .68
 Yes 117 (35.9) 22 (32.4)
 No 209 (64.1) 46 (67.6)
Clinical bowel perforation, No. of patients (%) 686 (96.9) 130 (97.0) .32
 Yes 24 (3.5) 7 (5.4)
 No 662 (96.5) 123 (94.6)
Clinical bowel obstruction, No. of patients (%) 692 (97.7) 132 (98.5) .14
 Yes 159 (23.0) 22 (16.7)
 No 533 (77.0) 110 (83.3)
Postoperative CEA, ng/mL, No. of patients (%) 660 (93.2) 124 (92.5) .82
 <5 628 (95.0) 119 (96.0)
 ≥5 32 (5.0) 5 (4.0)
Adjuvant chemotherapy arm,  
  No. of patients (%)
708 (100) 134 (100) .09
 5-FU/LV 365 (51.6) 58 (43.3)
 IFL 343 (48.4) 76 (56.7)
Median body mass index (range), kg/m2 28.3 (16.8254.5) 30.0 (17.6245.1) .07
Median physical activity (range), MET h/wk 7.6 (02125.4) 7.7 (02168.7) .67
Western dietary pattern, median score (range) 20.20 (21.73 to 9.35) 20.07 (21.60 to 4.31) .22
Consistent aspirin use, No. of patients (%) 698 (98.6) 125 (93.3) .001
 Yes 53 (7.6) 22 (17.6)
 No 645 (92.4) 103 (82.4)
(Table continues)
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known sample size and the number of cancer recurrence or death 
events for this analysis, we had 80% power to detect a hazard ratio 
of 0.55 for cancer recurrence or death.
Patient registration and clinical data collection were conducted 
by the CALGB Statistical Center, and analyses were performed in 
conjunction with CALGB statisticians on the basis of the database 
freeze date of March 31, 2009. Using Clark C (19), the com-
pleteness of follow-up for this study was 84.2%; applying Wu 
modification (20) to adjust for unreported deaths, a more realistic 
assessment was 85.9%.
Results
Baseline Characteristics According to Statin Use
The questionnaire completion rates between the two treatment 
arms of the trial were similar. Baseline characteristics for the 
patients for whom data on statin use were captured are presented 
in Table 1. Among 842 patients who completed the second ques-
tionnaire 6 months after completion of adjuvant chemotherapy, 
134 (15.9%) reported statin use. The median time from study 
entry (which had to be within 8 weeks of surgery) to statin assess-
ment was 13.5 months. Patients who reported statin use were 
older, had slightly higher BMI (P = .07), and were more likely to 
report consistent aspirin use. Other potentially prognostic patient 
and tumor characteristics were similar among statin users com-
pared with nonusers.
Impact of Statin Use on Cancer Recurrence and Death in 
the Overall Population
After a median follow-up of 6.5 years (10th and 90th percentiles: 
4.4 and 7.3 years, respectively), 198 of the 842 eligible patients 
recurred and 177 died. Compared with nonusers, statin users had 
similar DFS (log-rank P = .78, Figure 2, A), RFS (P = .73, data not 
shown), and OS (P = .32, Figure 2, B). Similar outcomes were 
Characteristic
Statin use after completion of adjuvant chemotherapy
No (n = 708) Yes (n = 134) P†
Regular COX-2 (PTGS2) inhibitor use,  
  No. of patients (%)
702 (99.2) 131 (97.8) .28
 Yes 33 (4.7) 9 (6.9)
 No 669 (95.3) 122 (93.1)
* CEA = carcinoembryonic antigen; COX = cyclooxygenase; ECOG = Eastern Cooperative Oncology Group; 5-FU/LV = bolus 5-fluorouracil and leucovorin; IFL = 
bolus 5-fluorouracil, leucovorin, and irinotecan; IU = international units; MET = metabolic equivalent task; PTGS2 = prostaglandin–endoperoxide synthase.
† P values were calculated by Fisher exact test for 2 × 2 categorical comparisons including sex (male or female), family history of colorectal cancer (yes or no), 
Eastern Cooperative Oncology Group performance status at the initiation of chemotherapy (0 or 1–2), depth of invasion into the bowel wall (T1 and T2 or T3 
and T4), the number of positive lymph nodes (1–3 or ≥4), lymphovascular invasion (yes or no), perineural invasion (yes or no), extravascular invasion (yes or no), 
KRAS mutation (yes or no), clinical bowl perforation (yes or no), clinical bowel obstruction (yes or no), CEA serum concentration (<5 or ≥5 ng/mL), adjuvant che-
motherapy arm, consistent aspirin use (any aspirin use on both Questionnaires 1 and 2, yes or no), and regular COX-2 (PTGS2) use (≥3 tablets of Celebrex or 
Vioxx per week, yes or no). A x2 test was used to calculate P for other categorical comparisons including race/ethnicity (white, black, or a combined category that 
included Hispanic, Asian, Native Hawaiian, Native American, Indian, Filipino, other, and unknown race/ethnicity) and grade of differentiation (well differentiated, 
moderately differentiated, or poorly differentiated and undifferentiated). The Kruskal–Wallis test was used to calculate P values for continuous variables including 
age (in years), median household income, body mass index at the initiation of chemotherapy (kg/m2), physical activity (metabolic equivalent task hours per week), 
and Western pattern diet. All statistical tests were two-sided.
‡ Analysis was on the basis of 1999 US census data as determined by patient zip code.
Table 1 (Continued).
Figure 2. Survival outcomes of statin 
users and nonusers from the Cancer and 
Leukemia Group B (CALGB) trial 89803. 
Kaplan–Meier curves of A) disease-free 
survival and B) overall survival of patients 
(n = 842) after a median follow-up of 6.5 
years. Error bars represent 95% confi-
dence intervals. Statistical significance 
was measured by the log-rank test. All 
P values were two-sided.
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again observed after adjusting for other predictors of cancer recur-
rence when statin users and nonusers were compared (Table 2). 
Compared with patients who did not report statin use following 
adjuvant chemotherapy, statin users had similar DFS (multivari-
able HR of cancer recurrence or death = 1.04, 95% confidence 
interval [CI] = 0.73 to 1.49). Also, statin use was not associated 
with a statistically significant improvement in RFS (adjusted HR of 
cancer recurrence = 1.14, 95% CI = 0.77 to 1.69) or OS (adjusted 
HR of death = 1.15, 95% CI = 0.77 to 1.71). Our results remained 
unchanged when we additionally adjusted our model for median 
household income (data not shown) and KRAS mutation status 
(Table 2).
To address the possibility that excluding recurrences and 
deaths within 90 days of statin assessment masked a potential ben-
efit of statin use, we repeated the analysis using all patients who 
had completed Questionnaire 2, and again DFS, RFS, and OS 
were similar. Furthermore, after extending the exclusion period 
from 90 to 180 days, DFS, RFS, and OS were again similar for 
statin users and nonusers (data not shown).
We also investigated the effect of the duration of statin use 
on patient outcome (Table 3). Recent statin use as reflected by 
reported use for 2 years or less did not lead to statistically sig-
nificantly improved DFS (adjusted HR of cancer recurrence or 
death = 1.12, 95% CI = 0.68 to 1.86), RFS (adjusted HR of cancer 
recurrence = 1.27, 95% CI = 0.74 to 2.18), or OS (adjusted HR of 
death = 1.25, 95% CI = 0.71 to 2.19). Moreover, increasing dura-
tion of use was not associated with patient survival (Ptrend = .63 for 
DFS, .63 for RFS, and .59 for OS).
Impact of Statin Use on Cancer Recurrence and Death 
According to KRAS Mutation Status
Among the 842 patients who reported on statin use following 
adjuvant chemotherapy, 394 (47%) had tumor tissue available for 
KRAS sequencing and 139 (35.3%) of these patients carried a 
KRAS mutation. Of the 139 tumors carrying a KRAS mutation, 96 
(69%) had a KRAS mutation in codon 12 and 43 (31%) had a mu-
tation in codon 13. DFS among statin users and nonusers, for both 
KRAS mutant and wild-type tumors, was similar (KRAS mutant 
tumors, adjusted HR of cancer recurrence or death = 1.21, 95% CI 
= 0.47 to 3.13; wild-type tumors, adjusted HR of cancer recurrence 
or death = 0.83, 95% CI = 0.41 to 1.71; Pinteraction = .84) (Figure 3, A 
and B, Table 2). RFS (KRAS mutant tumors, adjusted HR of cancer 
Table 2. Relationship between statin use and colon cancer recurrence and mortality in patients from the Cancer and Leukemia Group B 
trial 89803 (n = 842)
Outcome
Statin use reported after adjuvant chemotherapy
All Wild-type KRAS KRAS mutation
No Yes No Yes No Yes
Cancer recurrence or death from any cause
 No. of patients at risk 708 134 209 46 117 22
 No. of events 201 38 57 9 35 7
 Unadjusted HR (95% CI) 1.0 (referent) 1.05 (0.74 to 1.49) 1.0 (referent) 0.73 (0.36 to 1.47) 1.0 (referent) 1.09 (0.48 to 2.44)
 Adjusted HR (95% CI)* 1.0 (referent) 1.04 (0.73 to 1.49)† 1.0 (referent) 0.83 (0.41 to 1.71)‡ 1.0 (referent) 1.21 (0.47 to 3.13)‡
  Additionally adjusted for  
   KRAS mutation status
1.0 (referent) 1.05 (0.73 to 1.51) Pinteraction = .84§
Cancer recurrence
 No. of patients at risk 708 134 209 46 117 22
 No. of events 166 32 46 9 32 5
 Unadjusted HR (95% CI) 1.0 (referent) 1.07 (0.73 to 1.56) 1.0 (referent) 0.91 (0.45 to 1.86) 1.0 (referent) 0.86 (0.33 to 2.20)
 Adjusted HR (95% CI)* 1.0 (referent) 1.14 (0.77 to 1.69)† 1.0 (referent) 1.07 (0.51 to 2.22)‡ 1.0 (referent) 0.91 (0.30 to 2.79)‡
 Additionally adjusted for  
  KRAS mutation status
1.0 (referent) 1.15 (0.78 to 1.70) Pinteraction = .67§
Overall mortality
 No. of patients at risk 708 134 209 46 117 22
 No. of events 145 32 42 8 23 5
 Unadjusted HR (95% CI) 1.0 (referent) 1.22 (0.83 to 1.78) 1.0 (referent) 0.87 (0.41 to 1.85) 1.0 (referent) 1.26 (0.48 to 3.33)
 Adjusted HR (95% CI)* 1.0 (referent) 1.15 (0.77 to 1.71)† 1.0 (referent) 0.88 (0.39 to 1.97)‡ 1.0 (referent) 1.18 (0.38 to 3.69)‡
 Additionally adjusted for  
  KRAS mutation status
1.0 (referent) 1.16 (0.77 to 1.72) Pinteraction = .98§
* Multivariable HRs and 95% CIs were calculated by Cox proportional hazards models. CI = confidence interval; HR = hazard ratios.
† Adjusted for age (in years as a continuous variable), sex (male or female), family history of colorectal cancer (yes or no), baseline performance status (0 or 1–2), 
depth of invasion through bowel wall (T1, T2, T3, or T4), number of positive lymph nodes (1–3 or ≥4), perineural invasion (yes or no), extravascular invasion (yes 
or no), postoperative carcinoembryonic antigen (<5 or ≥5), treatment arm (bolus 5-fluorouracil and leucovorin or bolus 5-fluorouracil, leucovorin, and irinotecan), 
body mass index (in kg/m2 as a continuous variable), physical activity (in metabolic equivalent task hours per week as a continuous variable), Western pattern diet 
(as a continuous variable), and consistent aspirin use (any aspirin use on both questionnaires).
‡ Adjusted for age (in years as a continuous variable), sex (male or female), family history of colorectal cancer (yes or no), baseline performance status (0 or 1–2), 
depth of invasion through bowel wall (T1–T2 or T3–T4), number of positive lymph nodes (1–3 or ≥4), postoperative carcinoembryonic antigen serum levels (<5 
or ≥5 ng/mL), treatment arm (bolus 5-fluorouracil and leucovorin or the combination of irinotecan, bolus 5-fluorouracil, and leucovorin), body mass index (in kg/m2 
as a continuous variable), physical activity (in metabolic equivalent task hours per as a continuous variable), Western pattern diet (as a continuous variable), and 
consistent aspirin use (any aspirin use on both questionnaires).
§ Wald test of cross-product terms was used to calculate Pinteraction and was two-sided.
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recurrence = 0.91, 95% CI = 0.30 to 2.79; wild-type tumors, adjusted 
HR of cancer recurrence = 1.07, 95% CI = 0.51 to 2.22; Pinteraction = .67) 
(Table 2) and OS (KRAS mutant tumors, adjusted HR of death = 1.18, 
95% CI = 0.38 to 3.69; wild-type tumors, adjusted HR of survival = 
0.88, 95% CI = 0.39 to 1.97; Pinteraction = .98) (Table 2 and Figure 3, 
C and D) were also similar among statin users and nonusers.
Impact of Statin Use Across Strata of Other Predictors of 
Patient Outcome
We examined the influence of statin use during adjuvant chemo-
therapy on DFS across strata of other predictors of cancer out-
come (Figure 4). The relationship between statin use and DFS was 
similar across strata of age, sex, Eastern Cooperative Oncology 
Group performance status, the number of positive lymph nodes, 
depth of invasion through the bowel wall, treatment arm, BMI, 
physical activity, and Western pattern diet. Notably, the associa-
tion between statin use and DFS was also similar among consistent 
and inconsistent aspirin users (Pinteraction = .79). Moreover, regular 
use of cyclooxygenase-2 inhibitors (also known as prostaglandin–
endoperoxide synthase-2 inhibitors) did not modify the relation-
ship between statin use and patient outcome (Pinteraction = .56) (data 
not shown).
Relationship between Statin Use and Toxicity
We explored the influence of statins on the occurrence of the most 
common grade 3 or higher toxic effects seen in the treatment trial, 
as well as on cardiovascular events (Table 4) (11). The likelihood 
of developing grade 3 or higher toxic effects was similar for statin 
users of duration 2 years or more compared with nonusers after 
adjusting for potential confounding factors leukopenia (odds ratio 
[OR] = 1.10, 95% CI = 0.46 to 2.62), neutropenia (OR = 1.32, 95% 
CI = 0.71 to 2.44), nausea (OR = 0.68, 95% CI = 0.30 to 1.56), 
vomiting (OR = 0.91, 95% CI = 0.37 to 2.22), diarrhea (OR = 0.91, 
95% CI = 0.54 to 1.55), and fatigue (OR = 0.77, 95% CI = 0.32 to 
1.88). Also, the likelihood of developing grade 3 or higher cardio-
vascular toxicity was similar for statin users and nonusers, although 
the number of such events was small (n = 7 for nonusers and n = 1 
for statin users; adjusted OR = 1.08, 95% CI = 0.13 to 9.08).
Discussion
In this large cohort of stage III colon cancer patients treated with 
surgery and adjuvant chemotherapy, DFS, RFS, and OS were 
similar for statin users and nonusers. Recent statin use during the 
period of cancer diagnosis and treatment conferred no improve-
ment in DFS, RFS, or OS, and long-term regular statin use was 
similarly not associated with any benefit to survival. Moreover, the 
relationship between statin use and patient outcome was not mod-
ified by KRAS mutation status. Nonetheless, statin use did not 
increase the likelihood of chemotherapy-related adverse events. 
To our knowledge, this is the first study to prospectively examine 
the relationship between statin use and survival among patients 
with established colon cancer.
Because statins may interact with diverse signaling pathways 
that are critical for colon cancer development and progression, 
there has been intense interest in the potential of statins as chemo-
preventative and antitumor agents. A large observational study of 
1953 patients with colorectal cancer and 2015 control subjects 
demonstrated a statistically significant reduction in the risk of 
colorectal cancer with 5 or more years of statin use (6), as did two 
recent meta-analyses (7,8). Unfortunately, these findings were not 
confirmed in a large meta-analysis of epidemiological studies and 
randomized controlled trials (10) nor in several smaller observa-
tional studies (21–28).
Table 3. The association between statin use and colon cancer recurrence and mortality by the number of years of statin use in patients 
from the Cancer and Leukemia Group B trial 89803 (n = 839)*
Outcome
Statin use, y
Ptrend†0 ≤2 3–5 ≥6
Disease-free survival
 No. of patients at risk 708 54 42 35 —
 No. of events 201 17 10 11 —
 Unadjusted HR (95% CI) 1.0 (referent) 1.19 (0.72 to 1.95) 0.84 (0.45 to 1.59) 1.20 (0.65 to 2.19) .80
 Adjusted HR (95% CI) 1.0 (referent) 1.12 (0.68 to 1.86) 0.83 (0.43 to 1.58) 1.25 (0.67 to 2.32) .63
Recurrence-free survival
 No. of patients at risk 708 54 42 35 —
 No. of events 166 15 8 9 —
 Unadjusted HR (95% CI) 1.0 (referent) 1.26 (0.74 to 2.14) 0.82 (0.41 to 1.67) 1.17 (0.60 to 2.28) .86
 Adjusted HR (95% CI) 1.0 (referent) 1.27 (0.74 to 2.18) 0.89 (0.43 to 1.84) 1.28 (0.64 to 2.54) .63
Overall survival
 No. of patients at risk 708 54 42 35 —
 No. of events 145 14 9 9 —
 Unadjusted HR (95% CI) 1.0 (referent) 1.34 (0.77 to 2.31) 1.07 (0.54 to 2.09) 1.32 (0.67 to 2.58) .41
 Adjusted HR (95% CI) 1.0 (referent) 1.25 (0.71 to 2.19) 0.94 (0.47 to 1.91) 1.28 (0.64 to 2.57) .59
* Multivariable HRs and 95% CIs were calculated by Cox proportional hazards regression models and were adjusted for age (in years as a continuous variable), sex 
(male or female), family history of colorectal cancer (yes or no), baseline performance status (0 or 1–2), depth of invasion through bowel wall (T1, T2, T3, or T4), 
number of positive lymph nodes (1–3 or ≥4), perineural invasion (yes or no), extravascular invasion (yes or no), postoperative carcinoembryonic antigen (<5 or ≥5), 
treatment arm (bolus 5-fluorouracil and leucovorin or bolus 5-fluorouracil, leucovorin, and irinotecan), body mass index (in kg/m2 as a continuous variable), physical 
activity (in metabolic equivalent task hours per week as a continuous variable), Western pattern diet (as a continuous variable), and consistent aspirin use (any 
aspirin use on both questionnaires). CI = confidence interval; HR = hazard ratios.
† A linear test for trend was performed by entering the median value of each category of duration of statin use as a continuous variable in the model.
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In contrast, very few studies have addressed the role of statins 
among patients with established colorectal cancer. Siddiqui et al. 
(29) found that statin use was statistically significantly associated 
with less-advanced tumor stage and improved 5-year survival; 
however, statin use was assessed retrospectively (29). A single-arm, 
multicenter phase II study of infusional 5-fluorouracil, leucovorin, 
Figure 3. Survival outcomes of statin users and nonusers from the 
Cancer and Leukemia Group B (CALGB) trial 89803 stratified by 
KRAS mutation status. Kaplan–Meier curves of A) disease-free sur-
vival in KRAS wild-type patients, B) disease-free survival in KRAS 
mutant patients, C) overall survival in KRAS wild-type patients, and 
D) overall survival in KRAS mutant patients in those with tissue avail-
able for KRAS mutation testing (n = 394) after a median follow-up of 
6.5 years. Error bars represent 95% confidence intervals. Statistical 
significance was measured by the log-rank test. All P values were 
two-sided.
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and irinotecan plus simvastatin in previously untreated metastatic 
colorectal cancer patients has also been reported demonstrating 
reasonable tolerability, an overall response rate of 47%, median 
time to progression of 9.9 months, and median survival of 21.8 
months (30). However, the added contribution of simvastatin 
to chemotherapy is impossible to determine in the context of 
the trial’s single-arm design. Finally, National Surgical Adjuvant 
Breast and Bowel Project protocol P-5, the Statin Polyp Prevention 
Trial, was recently activated and is currently enrolling patients. 
This large study plans to randomize 1740 patients with resected 
stage I or II colon cancer to rosuvastatin vs placebo for 5 years, 
with a primary endpoint of adenomatous polyp development, 
metachronous colorectal cancer, or colon cancer recurrence. Data 
will not be available for several years.
There are several mechanisms through which statin exposure 
may influence survival after a diagnosis of colon cancer. Statins 
have been shown to inhibit proliferation (31,32), induce apoptosis 
(33,34), inhibit angiogenesis (35,36), affect cell–cell adhesion (37), 
prevent metastasis (38), and decrease inflammation (39, 40). 
A leading hypothesis to explain the antitumor activity of statins in 
colorectal cancer revolves around the suppression of farnesylation 
of RAS, thus preventing RAS activation, a key oncogenic event. 
In fact, several pharmacological inhibitors of farnesylation have 
been examined in patients with KRAS-driven malignancies (41–44). 
However, in our analysis, statin use was not associated with 
improved survival in patients with either KRAS-mutated or wild-
type colon tumors. Moreover, our analysis found that the relation-
ship between statin use and patient outcome did not differ by 
aspirin or cyclooxygenase-2 inhibitor use.
There are several advantages to using a cohort within a clinical 
trial sponsored by the National Cancer Institute. First, all patients 
had stage III cancer, reducing the impact of heterogeneity by disease 
Multivariable HR (95% CI)
P interaction
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Figure 4. Risk of cancer recurrence and 
death among statin users and nonusers 
across strata of predictors of cancer out-
come. Multivariable hazard ratios (HRs) and 
95% confidence intervals (CIs) for cancer re-
currence and death (disease-free survival) 
were calculated by Cox proportional haz-
ards regression models. Wald test of 
cross-product terms was used to calculate 
Pinteraction and was two-sided. ASA = aspirin; 
BMI = body mass index; ECOG = Eastern 
Cooperative Oncology Group; IFL = irino-
tecan, bolus 5-FU, LV; MET = metabolic 
equivalent task; PS = performance status; T 
= depth of invasion through bowel wall; 
5-FU/LV = bolus 5-fluorouracil/leucovorin; .
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a statistically significant treatment effect. The hazard ratios we 
obtained were in the 1.0–1.1 range, and no trends toward a positive 
or negative association were detected. Second, patients who enroll 
in randomized trials may differ from the population at large. 
However, because the study included patients from community 
and academic centers throughout North America, our findings 
should reflect the general US population. Third, because we relied 
on self-reported statin use, misclassification of exposure is possible. 
However, previous studies have demonstrated that such data are 
reliable (6). Furthermore, statin use was recorded before any 
knowledge of cancer-related outcomes, thus reducing the likeli-
hood of reporting biases. Fourth, patients who are prescribed 
statins may differ from the general population by socioeconomic 
status (45); lifestyle factors such as diet, BMI, and physical activity; and 
utilization of medical care and preventative health practices (46). 
Our study was controlled for median household income, dietary 
pattern, BMI, physical activity, performance status, and other po-
tentially prognostic variables. However, residual confounding 
from unknown variables is possible.
Another possible limitation is that we were unable to assess the 
individual impact of different statins on patient outcome, because 
information on the type of statin used by each patient was not 
collected on the questionnaires. Although some hypotheses 
suggest that lipophilic and hydrophilic statins may have distinct 
effects, previous studies have not been able to show a differential 
impact on colorectal cancer risk, although this has not been well 
studied. Finally, although many studies have reported that the 
presence of any KRAS mutation is associated with resistance to 
antibodies against the epidermal growth factor receptor, such as 
cetuximab (47–50), recent data indicate that KRAS codon 12 and 
13 mutations may result in biologically and functionally distinct 
proteins, with different treatment responses to cetuximab (51). 
Unfortunately, we were unable to evaluate the effect of statins 
among tumors with specific KRAS mutations because of the 
limited number of patients with available KRAS data.
In conclusion, our large prospective study of stage III colon 
cancer patients found that DFS, RFS, and OS were similar for 
statin users and nonusers, independent of KRAS mutation. 
Importantly, statin use was not associated with increased toxicity in 
the patient population. We eagerly await the results of the Statin 
Polyp Prevention Trial (protocol P-5) initiated by the National 
Surgical Adjuvant Breast and Bowel Project. Additional studies are 
also needed to elucidate the potential role of statin use in colon 
cancer recurrence and patient outcome.
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